IMRX Immuneering Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1790340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.4%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.5%
ROA-31.4%
ROIC (approx.)-105.3%
Asset turnover—
Leverage & solvency
Liabilities / assets7.6%
Debt / equity0.00x
Current ratio13.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $42.05M | $47.96M |
| SG&A expense | $17.30M | $16.08M |
| Operating income | -$59.38M | -$64.07M |
| Income tax | $0 | — |
| Net income | -$56.02M | -$61.04M |
| EBITDA | -$59.05M | -$63.72M |
| EPS (basic) | -1.27 | -2.04 |
| EPS (diluted) | -1.27 | -2.04 |
| Weighted avg. shares (diluted) | 44.01M | 29.98M |
| Balance sheet | ||
| Cash & equivalents | $128.65M | $36.14M |
| Short-term investments | — | $0 |
| Current assets | $176.25M | $39.59M |
| PP&E, net | $938,481 | $1.12M |
| Goodwill | $6.69M | $6.69M |
| Intangibles | $321,147 | $350,413 |
| Total assets | $231.99M | $52.71M |
| Current liabilities | $10.07M | $7.50M |
| Total liabilities | $13.50M | $11.33M |
| Shareholders' equity | $218.48M | $41.39M |
| Cash flow statement | ||
| Operating cash flow | -$45.34M | -$55.00M |
| Capital expenditure | $142,226 | $84,875 |
| Free cash flow | -$45.49M | -$55.08M |
| Investing cash flow | -$88.74M | $26.43M |
| Financing cash flow | $226.58M | $5.30M |
| Depreciation & amortization | $324,517 | $355,807 |
| Stock-based compensation | $6.31M | $6.50M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.